Literature DB >> 7883424

Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival.

E George1, T J Lillemoe, L B Twiggs, T Perrone.   

Abstract

To ascertain whether uterine malignant mixed müllerian tumors are biologically distinct from high-grade endometrial carcinomas (FIGO grade 3), we compared patient survival in 32 and 39 cases, respectively. The Cox proportional hazard model was employed to determine whether tumor type was an independent predictor of survival. The survival of patients with MMMT was also compared to that of patients with serous adenocarcinoma and clear cell carcinoma. The 5-year overall and disease-free survival were significantly lower for malignant mixed müllerian tumors (25% and 11%) than for high-grade endometrial carcinomas (64% and 56%). Using the Cox proportional hazard model, tumor type (MMMT vs. high-grade endometrial carcinoma) was a statistically significant predictor of survival after other important prognostic variables such as pathologic stage, depth of myometrial invasion, and vascular invasion had been taken into account. The increased aggressiveness of MMMT appears most attributable to their tendency to reach a more advanced stage by the time of clinical presentation and to their greater propensity for upper abdominal dissemination. The survival of patients with MMMT was also lower than that of patients with the special histologic variants of endometrial carcinoma, serous adenocarcinoma and clear cell carcinoma, which are recognized for their unusually aggressive clinical behavior. These results indicate that uterine malignant mixed müllerian tumors are clinically more aggressive than high-grade endometrial carcinomas and should continue to be recognized as a distinct entity.

Entities:  

Mesh:

Year:  1995        PMID: 7883424     DOI: 10.1097/00004347-199501000-00007

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  8 in total

1.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.

Authors:  A C Ansink; P A Cross; P Scorer; A de Barros Lopes; J M Monaghan
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 3.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

4.  Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.

Authors:  İrfan Cicin; Tahsin Özatlı; Esma Türkmen; Türkan Özturk; Melike Özçelik; Devrim Çabuk; Ayşe Gökdurnalı; Özlem Balvan; Yaşar Yıldız; Metin Şeker; Nuriye Özdemir; Burcu Yapar; Özgür Tanrıverdi; Yusuf Günaydin; Serkan Menekşe; Berna Öksüzoğlu; Asude Aksoy; Bülent Erdogan; M Bekir Hacıoglu; Erkan Arpaci; Alper Sevinç
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

5.  Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.

Authors:  Hyun Ju Lee; Jong Jin Lee; Jeong Yeol Park; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim; Joo Hyun Nam
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

6.  Ovarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review.

Authors:  Stoyan Kostov; Yavor Kornovski; Yonka Ivanova; Deyan Dzhenkov; George Stoyanov; Stanislav Stoilov; Stanislav Slavchev; Ekaterina Trendafilova; Angel Yordanov
Journal:  Diagnostics (Basel)       Date:  2020-12-11

7.  Uterine carcinosarcoma: A 10-year single institution experience.

Authors:  Leana Terblanche; Matthys H Botha
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

8.  The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma.

Authors:  Hae Jin Park; Hak Jae Kim; Hong-Gyun Wu; Hans Kim; Sung Whan Ha; Soon-Beom Kang; Yong-Sang Song; Noh-Hyun Park; Jae-Won Kim
Journal:  Radiat Oncol J       Date:  2011-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.